Insider buying last 90 days
No open-market insider purchases were filed for DNTH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Dianthus Therapeutics reported third-quarter 2026 results on 4 November, posting a loss that beat revenue estimates and compared to a loss of $0.97 per share a year ago. The company highlighted progress on its neuromuscular franchise, including claseprubart, which is in Phase 3 EMERGE trials across generalized Myasthenia Gravis, CIDP and MMN. Separately, Dianthus announced inducement grants for newly-hired employees and confirmed participation in five investor conferences during November, while an officer filed notice of a proposed sale of 124,042 shares valued at $10.67 million.
DNTH closed at $90.00, up 4.6%, sitting above both its 50-day average of $89.73 and 200-day average of $86.14, with the 50-day above the 200-day. The GekkoIndex reads 53.3, placing the stock in the Neutral zone, down 6.4 points over five sessions. Price remains 17.6% below Gekko Fair Value of $109.27, a gap wider than the typical 5% threshold watched for valuation extremes.
The next earnings date falls on 8 March 2027, 118 days out, outside the typical 20-trading-day holding window. Smart money readings show no insider, Congress, or unusual options activity in their respective 90-day and 30-day windows. Seasonality is a headwind: over five years, the next 20 trading days from this point averaged a -7.9% return, rising in just 1 of those years. Consensus among 10 analysts remains all-buy, with a target of $139.06 implying 54.5% upside.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Dianthus Therapeutics scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
Above 50 and 200-day
Close $91.81 is above the 50-day ($88.45) and 200-day ($86.93) averages, and the 50-day is above the 200-day.
See the chart50.4, Neutral
Reading 50.4 is in the Neutral zone.
See the GekkoIndex15.5% below
Price is 15.5% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 113 days
Next report Mar 8, 2027, 113 days away — outside a typical 20-trading-day hold.
See earnings−20.6% on average
From this point in the calendar, the next 20 trading days averaged −20.6% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Dianthus Therapeutics closed at $91.81 on Nov 13, 2026, +137.1% over the past year, inside a 52-week range of $34.29 to $117.88.
Use the left and right arrow keys to read daily values.
Put DNTH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Dianthus Therapeutics works on medicines for people with serious autoimmune conditions, operating as a clinical-stage biotechnology company. Its furthest-along candidate, claseprubart, is a monoclonal antibody built for a longer half-life, stronger potency, and narrow targeting of only the active form of the C1s complement protein. It is best known for this program among its pipeline of experimental treatments.
The company also has a second candidate, DNTH212, described as a bifunctional fusion protein. This molecule is designed to act on plasmacytoid dendritic cells through BDCA2 to lower Type 1 interferon output, while at the same time blocking BAFF and APRIL to limit B cell activity. As a clinical-stage business, Dianthus Therapeutics centers its work on advancing these drug candidates through development rather than on selling approved products.
Dianthus Therapeutics was established in 2019 and has its headquarters in New York, New York. Its shares are listed on the NASDAQ under the ticker DNTH.
Dianthus Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.4, in the Neutral zone, down 6.2 points over five sessions.
Down 6.2 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 31 | +6.2% | +12.7% |
| Accumulation | 188 | +2.5% | +8.0% |
| Neutral (current zone) | 425 | +0.8% | +4.2% |
| Distribution | 41 | +3.6% | +8.3% |
| Selling | 17 | +9.6% | +22.4% |
Average DNTH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Dianthus Therapeutics trades 15.5% below Gekko Fair Value of $108.71, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Dianthus Therapeutics shares are worth, recalculated every trading day.
$108.71
Gekko Fair Value, Nov 14, 2026
15.5% Undervalued
At the end of Aug 2026 the price was 16.0% below the estimate.
No open-market insider purchases were filed for Dianthus Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for DNTH in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in DNTH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Dianthus Therapeutics has been buying back its own shares.
From company filings.
Dianthus Therapeutics reports on Mar 8, 2027 (113 days away), and beat the EPS estimate in 1 of its last 8 reports.
Mar 8, 2027
113 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$0.90 est −$0.85 | $761K est $297K | +6.1% |
| Mar 9, 2026 | −$1.43 est −$0.98 | $284K est $552K | +33.3% |
| Nov 5, 2025 | −$0.97 est −$0.86 | $396K est $398K | +9.7% |
| Aug 7, 2025 | −$0.88 est −$0.86 | $193K est $865K | −8.0% |
| May 12, 2025 | −$0.82 est −$0.71 | $1.16M est $807K | −3.8% |
| Mar 11, 2025 | −$0.81 est −$0.76 | $1.33M est $955K | −10.0% |
| Nov 7, 2024 | −$0.72 est −$0.59 | $2.17M est $844K | −1.2% |
| Aug 8, 2024 | −$0.51 est −$0.55 | $1.86M est $320K | +6.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Dianthus Therapeutics is $139.25, +51.7% from the last close, from 10 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 10 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Stifel Nicolaus | $133 | +44.9% |
| Nov 6 | H.C. Wainwright | $158 | +72.1% |
| Nov 5 | Wells Fargo | $135 | +47.0% |
| Nov 5 | Stifel Nicolaus | $133 | +44.9% |
| Nov 5 | Wedbush | $122 | +32.9% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Dianthus Therapeutics averaged −20.6% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −9.2% | 2 of 5 |
| Next 10 trading days | −11.0% | 2 of 5 |
| Next 15 trading days | −12.2% | 1 of 5 |
| Next 20 trading days | −20.6% | 1 of 5 |
| Next 30 trading days | −27.5% | 1 of 5 |
For scale, DNTH’s typical 20-trading-day move in either direction is about 11.4%.
Dianthus Therapeutics’s market cap is $5.17B and revenue of $2.72M over the last twelve months.
Coverage of Dianthus Therapeutics this week reads neutral: 1 positive, 6 neutral and 4 negative headlines.
Dianthus Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Dianthus Therapeutics’s market cap is $5.17B at the Nov 13, 2026 close of $91.81, with 56.31M shares outstanding.
The consensus analyst 12-month price target for Dianthus Therapeutics is $139.25, +51.7% from the last close. Of the 10 firms that rated the stock in the last 90 days, 10 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Dianthus Therapeutics is undervalued: the Nov 13, 2026 close of $91.81 is 15.5% below Gekko Fair Value of $108.71. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Dianthus Therapeutics is expected to report on Mar 8, 2027 (113 days away). Analysts expect earnings of −$0.96 per share on revenue of $448K. Dianthus Therapeutics beat the earnings estimate in 1 of its last 8 reports, moving 9.8% on average across the report.
Dianthus Therapeutics’s 52-week high is $117.88 and its 52-week low is $34.29; it closed at $91.81 on Nov 13, 2026, +137.1% over the past year. Over the last five years the shares peaked at $122.08 on Nov 15, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.